Bridgebio Oncology Therapeutics earnings were -$154.1M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest BBOT earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$42.1M, up 8.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, BBOT reported annual earnings of -$134.0M, with 80.5% growth. The next BBOT earnings date is Aug 11, 2026.
Bridgebio Oncology Therapeutics Earnings Reports & History FAQ
What were Bridgebio Oncology Therapeutics's earnings last quarter?
Bridgebio Oncology Therapeutics (NASDAQ: BBOT) reported Q1 2026 earnings per share (EPS) of -$526.11, up 870.15% year over year. Total BBOT earnings for the quarter were -$42.11 million. In the same quarter last year, Bridgebio Oncology Therapeutics's earnings per share (EPS) was -$54.23.
When does Bridgebio Oncology Therapeutics report earnings?
The next BBOT earnings date is Aug 11, 2026. Add BBOT to your watchlist to be reminded of Bridgebio Oncology Therapeutics's next earnings date.
Is Bridgebio Oncology Therapeutics profitable or losing money?
As of the last Bridgebio Oncology Therapeutics earnings report, Bridgebio Oncology Therapeutics is currently losing money. Bridgebio Oncology Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$154.10 million, a 90.5% increase year over year.
What was BBOT's earnings growth in the past year?
As of Bridgebio Oncology Therapeutics's earnings date in Q3 2026, Bridgebio Oncology Therapeutics's earnings has grown year over year. BBOT earnings in the past year totalled -$154.10 million.
What are Bridgebio Oncology Therapeutics's earnings expectations?
The current EPS estimate for Bridgebio Oncology Therapeutics's earnings report in Aug 11, 2026 is -$0.55.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.